Day One Biopharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Day One Biopharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Day One Biopharmaceuticals: 5 sponsored US clinical trials, 3 recruiting.
Day One Biopharmaceuticals sponsors 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Low Grade Glioma, with 2 trials.
Upper-quartile sponsor footprint
Day One Biopharmaceuticals sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06752681
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
NCT07121829
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
NCT04985604
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 1 |
What is open in the Day One Biopharmaceuticals pipeline
3 recruiting of 5 indexed (60% open).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Low Grade Glioma (2 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Day One Biopharmaceuticals: open-pipeline peers nationwide
Peers matched on 5 registered trials and 60% open enrollment, not the therapeutic-area sidebar.
Day One Biopharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 60% open enrollment (± trial volume)
- Alaska Native Tribal Health Consortium · 60% recruiting · 5 trials
- Anwaar Saeed · 60% recruiting · 5 trials
- Autolus Limited · 60% recruiting · 5 trials
- Beam Therapeutics · 60% recruiting · 5 trials
Related
What to do with this Day One Biopharmaceuticals page
5 registered trials is a research-attention snapshot, not an endorsement of Day One Biopharmaceuticals or any single study.
- 3 of Day One Biopharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Low Grade Glioma is the condition Day One Biopharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Low Grade Glioma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Day One Biopharmaceuticals pipeline card: 5 registered trials from official public datasets.Report a data error.